Trial Outcomes & Findings for Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study (NCT NCT01804257)

NCT ID: NCT01804257

Last Updated: 2017-06-16

Results Overview

Comparison of the detection rate of sensor-enabled placebo tablet ingestion using wireless observation (wirelessly observed therapy) to directly observed ingestion. Positive detection accuracy (PDA) for wirelessly observed therapy defined as the number of sensor ingestions detected by wireless observation, divided by the number confirmed ingestions using direct observation. PDA summarized as mean and 95% confidence interval.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

28 participants

Primary outcome timeframe

4 weeks

Results posted on

2017-06-16

Participant Flow

Participant milestones

Participant milestones
Measure
Digital Health Feedback System (DHFS)
Ingestion Sensor, Wearable Sensor Digital Health Feedback System: The digital health offering passively collects and records medication-taking behavior and other habits of daily living
Overall Study
STARTED
28
Overall Study
COMPLETED
27
Overall Study
NOT COMPLETED
1

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Digital Health Feedback System (DHFS)
n=28 Participants
Ingestion Sensor, Wearable Sensor Digital Health Feedback System: The digital health offering passively collects and records medication-taking behavior and other habits of daily living
Age, Customized
42.8 years
STANDARD_DEVIATION 12.7 • n=39 Participants
Sex: Female, Male
Female
10 Participants
n=39 Participants
Sex: Female, Male
Male
18 Participants
n=39 Participants
Type of Mental Health Disorder
Bipolar Disorder
12 Participants
n=39 Participants
Type of Mental Health Disorder
Schizophrenia
16 Participants
n=39 Participants

PRIMARY outcome

Timeframe: 4 weeks

Population: 28 individuals with bipolar disorder (12) or schizophrenia (16)

Comparison of the detection rate of sensor-enabled placebo tablet ingestion using wireless observation (wirelessly observed therapy) to directly observed ingestion. Positive detection accuracy (PDA) for wirelessly observed therapy defined as the number of sensor ingestions detected by wireless observation, divided by the number confirmed ingestions using direct observation. PDA summarized as mean and 95% confidence interval.

Outcome measures

Outcome measures
Measure
Digital Health Feedback System (DHFS)
n=28 Participants
Ingestion Sensor,...
Positive Detection Accuracy
94 percentage of observed ingestions
Interval 85.4 to 100.0

SECONDARY outcome

Timeframe: 8 weeks

Characterize, using summary (descriptive) statistics, the incidence and nature of system-related adverse events (AEs) and serious adverse events (SAEs) that are reported by study investigators over the course of the study

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 4 weeks

Characterize, using summary (descriptive) statistics, medication-taking behavior in free-living environment. Taking adherence defined as the number of ingestion sensors detected by the DHFS in the free-living environment, divided by the prescribed (planned) number of ingestions. Scheduling adherence defined as number of ingestion sensors detected by the DHFS within a ± 2-hour time window around the prescribed (planned) dosing time, divided by the total number of ingestion sensors detected by the DHFS.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 4 weeks

Characterize, using summary (descriptive) statistics, heart rate and rest/activity patterns in a free-living environment. Activity defined as the number of hours per day with recorded a recorded step rate ≥ 60 steps per minute

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 4 weeks

Characterize, using summary (descriptive) statistics, the use of the digital health feedback system and its components by patients, caregivers, and healthcare providers. Use captured utilizing numeric scores collected from a standardized instrument, focusing on overall comfort and ease of DHFS use.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 4 weeks

Feedback and suggestions from patients, caregivers, and healthcare providers regarding system metrics and summary presentations of medication-taking, biometrics, and activities of daily living. Feedback includes free text and descriptive statistics summarizing numeric scores collected from a standardized instrument focusing on overall satisfaction with the DHFS and its components.

Outcome measures

Outcome data not reported

Adverse Events

Digital Health Feedback System (DHFS)

Serious events: 1 serious events
Other events: 6 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Digital Health Feedback System (DHFS)
n=28 participants at risk
DHFS
Psychiatric disorders
schizoaffective disorder
3.6%
1/28 • Number of events 1

Other adverse events

Other adverse events
Measure
Digital Health Feedback System (DHFS)
n=28 participants at risk
DHFS
Skin and subcutaneous tissue disorders
Self-limited rash
21.4%
6/28 • Number of events 9

Additional Information

John M. Kane MD

Zucker Hillside Hospital, Glen Oaks, NY

Phone: (718) 470-8141

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place